Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Journal article published in 2019 by
Frank G. Rücker,
Mridul Agrawal,
Andrea Corbacioglu,
Daniela Weber,
Silke Kapp-Schwoerer,
Verena I. Gaidzik,
Nikolaus Jahn,
Thomas Schroeder,
Mohammed Wattad,
Michael Lübbert,
Elisabeth Koller,
Thomas Kindler,
Katharina Götze 
,
Mark Ringhoffer,
Jörg Westermann
and other authors.
,
Mark Ringhoffer,
Jörg Westermann
and other authors.
This paper was not found in any repository; the policy of its publisher is unknown or unclear.
Full text: Unavailable
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points MRD assessment in t(8;21) AML allows identification of patients at high relapse risk at defined time points during treatment and follow-up. MRD− after treatment is the most favorable factor for relapse risk and survival, and serial MRD analyses define cutoffs predicting relapse.